Richard Surwit

Richard S. Surwit, Ph.D.

Chief Executive Officer

Richard S. Surwit, Ph.D. (rsurwit@sengenix.com) is Professor of Psychiatry and Behavioral Sciences and the Former Vice Chairman for Research in the Department of Psychiatry at Duke University. He has over 35 years in managing research and development and holds six U.S. patents. As Founder and Chairman of ZyCare, Inc., Dr. Surwit has over 25 years experience in the diagnostics industry. ZyCare licensed a major product to Roche Diagnostics in 1999 and was acquired by Alere, Inc. in 2009.

Homme W. Hellinga, Ph.D.

Chief Scientific Officer

Homme W. Hellinga, Ph.D. (hhellinga@sengenix.com) is James B. Duke Professor of Biochemistry at Duke University. He has 25 years of experience in protein engineering and biosensor development. Dr. Hellinga has numerous academic awards and honors and holds seven U.S. patents on engineered proteins. He has developed an FRS that has been licensed by a major diagnostic company. Two commercially successful companies, Precision Biosciences and Protabit have already been founded involving technologies developed in his laboratory for non-diagnostic applications.

Sandra E. Cummings, MBA

Chief Financial Officer

Sandra E. Cummings, MBA (scummings@sengenix.com) has 13 years of business development management experience in the telecommunications industry (Nortel Networks) and 14 years of management experience in medical diagnostics. She was President and COO of ZyCare, Inc. where she managed the development, clinical trials, and commercial launch of its CoagCare Anticoagulation Management System until ZyCare was acquired by Alere, Inc. She has been a Principal Investigator on both Phase I and II SBIR grants.

Ralph Snyderman, M.D.

Senior Medical Advisor

Ralph Snyderman, M.D. is Chancellor Emeritus, Duke University and James B. Duke Professor of Medicine. During his tenure at Duke, he oversaw the development of the Duke University Health System which was one of the first and few fully integrated academic health systems in the country and served as its first President and CEO. Prior to this, he was Senior Vice President for Medical Research and Development at Genentech Inc. Dr. Snyderman is a leading figure in the field of personalized health care, an evolving model of national health care delivery. Dr. Snyderman is a member of the Institute of Medicine and the American Academy of Arts & Sciences.

Lawrence Cohen

Director

Lawrence Cohen (lcohen@sengenix.com) has held leadership positions in the InVitro Diagnostic industry for more than 30 years. He was President of International Technidyne Corporation (ITC), a subsidiary of Thoratec for 9 years until it was sold in 2010. Prior to that he was CEO of HemoSense, a Point-of Care start-up that was later sold to Alere, Inc. He has also held the positions of Worldwide Group VP, VP International and VP Marketing and Sales at Ortho Clinical Diagnostics (OCD), a Johnson & Johnson Company. Prior to OCD, Larry held leadership and senior management positions at Instrumentation Laboratory, Fisher Group and Beckman Instruments.